Recently, our company obtained the patent certificate for invention issued by the China National Intellectual Property Administration for two products: [DNA-RNA hybrid double strand specific conjugate in promoting nucleic acid replication and application in the detection of SARS-CoV-2] (patent number: ZL 2021 1 0500362.7); and [Molecular lock and application of a specific amplification target gene] (patent number: ZL 2021 1 0632780.1). This successful authorization is not only a major positive news for the research and development achievements of HymonBio, but also a tribute to the continuous efforts and innovative technological research of the company over the years.
DNA-RNA hybrid double strand specific conjugate in promoting nucleic acid replication and application in the detection of SARS-CoV-2
This technology aims to be applied to multiple pathogen detection, enabling entire process monitoring from sampling to detection, improving detection sensitivity and specificity, and effectively avoiding false negative and false positive results.
Molecular lock and application of a specific amplification target gene
This technology aims to solve the interference of wild-type genes on the amplification of mutant genes, improve the accuracy of mutant gene detection, and the 80% to 90% of “noise” removal, which can specifically identify and amplify mutant genes. The sensitivity of detection of mutated genes can reach 1 in 10,000.
Post time: May-15-2023